{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:00:55Z","timestamp":1789966855357,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,20]]},"DOI":"10.7759\/cureus.116611","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:06:51Z","timestamp":1789963611000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study"],"prefix":"10.7759","author":[{"given":"Hazuki","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Kurioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02537-z","article-title":"Diabetic kidney disease: the kidney disease relevant to individuals with diabetes","volume":"28","author":"Kanasaki K","year":"2024","unstructured":"Kanasaki K, Ueki K, Nangaku M. Diabetic kidney disease: the kidney disease relevant to individuals with diabetes. Clin Exp Nephrol. 2024, 28:1213-20. 10.1007\/s10157-024-02537-z","journal-title":"Clin Exp Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0879-4","article-title":"Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes","volume":"18","author":"Wada T","year":"2014","unstructured":"Wada T, Haneda M, Furuichi K, et al.. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014, 18:613-20. 10.1007\/s10157-013-0879-4","journal-title":"Clin Exp Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","unstructured":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022, 102.S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease","volume":"6","author":"Georgianos PI","year":"2021","unstructured":"Georgianos PI, Agarwal R. Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. Kidney Int Rep. 2021, 6:2281-91. 10.1016\/j.ekir.2021.05.027","journal-title":"Kidney Int Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02223-0","article-title":"A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches","volume":"39","author":"Mima A","year":"2022","unstructured":"Mima A. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches. Adv Ther. 2022, 39:3488-500. 10.1007\/s12325-022-02223-0","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2521086","article-title":"Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review","volume":"21","author":"Mima A","year":"2025","unstructured":"Mima A, Nomura A, Yasuzawa T. Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review. Expert Rev Clin Immunol. 2025, 21:921-8. 10.1080\/1744666X.2025.2521086","journal-title":"Expert Rev Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt B","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021, 385:2252-63. 10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.04.012","article-title":"Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD","volume":"10","author":"Yamanouchi M","year":"2025","unstructured":"Yamanouchi M, Oba Y, Kamido H, et al.. Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD. Kidney Int Rep. 2025, 10:2461-5. 10.1016\/j.ekir.2025.04.012","journal-title":"Kidney Int Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf292","article-title":"Real-world analysis of the impact of finerenone on estimated glomerular filtration rate and albuminuria in patients with diabetic kidney disease","volume":"18","author":"Ichijo K","year":"2025","unstructured":"Ichijo K, Yamaguchi R, Takashima H, Kobayashi H, Maruyama T, Abe M. Real-world analysis of the impact of finerenone on estimated glomerular filtration rate and albuminuria in patients with diabetic kidney disease. Clin Kidney J. 2025, 18:sfaf292. 10.1093\/ckj\/sfaf292","journal-title":"Clin Kidney J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100318","article-title":"Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study","volume":"24","author":"Kawaguchi Y","year":"2024","unstructured":"Kawaguchi Y, Hajika Y, Ashida N, et al.. Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study. Metabol Open. 2024, 24:100318. 10.1016\/j.metop.2024.100318","journal-title":"Metabol Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-025-00839-5","article-title":"Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use","volume":"16","author":"Yamao Y","year":"2025","unstructured":"Yamao Y, Ota M, Kanasaki K. Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use. Diabetol Int. 2025, 16:717-25. 10.1007\/s13340-025-00839-5","journal-title":"Diabetol Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris GL","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al.. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015, 314:884-94. 10.1001\/jama.2015.10081","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2023.100251","article-title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25\u00a0mL\/min\/1.73\u00a0m(2)","volume":"19","author":"Mima A","year":"2023","unstructured":"Mima A, Lee R, Murakami A, et al.. Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25\u00a0mL\/min\/1.73\u00a0m(2). Metabol Open. 2023, 19:100251. 10.1016\/j.metop.2023.100251","journal-title":"Metabol Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100294","article-title":"Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease","volume":"22","author":"Mima A","year":"2024","unstructured":"Mima A, Saito Y, Matsumoto K, Nakamoto T, Lee S. Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease. Metabol Open. 2024, 22:100294. 10.1016\/j.metop.2024.100294","journal-title":"Metabol Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al.. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014, 129:587-97. 10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000083982.74108.54","article-title":"Nongenomic vascular action of aldosterone in the glomerular microcirculation","volume":"14","author":"Arima S","year":"2003","unstructured":"Arima S, Kohagura K, Xu HL, et al.. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003, 14:2255-63. 10.1097\/01.asn.0000083982.74108.54","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet MH","year":"2017","unstructured":"Muskiet MH, Tonneijck L, Smits MM, et al.. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017, 13:605-28. 10.1038\/nrneph.2017.123","journal-title":"Nat Rev Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/531635-association-of-finerenone-dose-and-estimated-glomerular-filtration-rate-egfr-slope-changes-in-patients-with-diabetic-kidney-disease-a-real-world-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:06:53Z","timestamp":1789963613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/531635-association-of-finerenone-dose-and-estimated-glomerular-filtration-rate-egfr-slope-changes-in-patients-with-diabetic-kidney-disease-a-real-world-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.116611","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}